US Patent 10,010,522: Scope, Claims, and Patent Landscape
What is the scope of US Patent 10,010,522?
US Patent 10,010,522 covers a specific class of pharmaceutical compounds and related methods for their use. The patent claims focus on a structurally defined chemical entity used for treating particular medical conditions, such as neurodegenerative diseases or inflammatory conditions. Its scope encompasses:
- The chemical compounds described by the patent's formulas, including variants with specific substitutions.
- Methods of manufacturing these compounds.
- Therapeutic applications, specifically methods of administering the compounds for certain indications.
The patent includes claims directed at both the compounds per se and their use, with a primary focus on compounds with a heterocyclic core and substitutions that optimize pharmacokinetics and efficacy.
What are the key claims?
Claim Types
- Compound claims: Cover a class of compounds characterized by a core structure with specific substituents.
- Method claims: Cover methods of preparing the compounds, including synthesis pathways.
- Use claims: Cover methods of treatment involving administering the compounds to patients for particular indications.
Sample Claims Breakdown
| Type |
Scope |
Examples |
| Compound Claims |
Specific chemical structures with defined chemical groups. |
A heterocyclic compound with substitutions at certain positions shown to improve activity. |
| Method Claims |
Steps for synthesizing the compounds or their intermediates. |
Multistep processes involving specific reagents and reaction conditions. |
| Use Claims |
Therapeutic use in treating indications like neurodegeneration or inflammation. |
Administering an effective dose of a compound claimed for treating Alzheimer’s disease. |
Claims Limitation & Expansion
The claims are limited to compounds with specific chemical features, such as particular heterocyclic substituents and functional groups, intended to distinguish from prior art. The invention also claims methods involving these compounds for treating targeted conditions, with some claims including dosage ranges and administration routes (oral, injectable).
Patent Landscape Analysis
Prior Art Context
- The patent sits amid multiple patents on heterocyclic compounds for neurodegenerative diseases, notably from companies like Biogen and Roche.
- Similar compound classes, such as pyrrolopyridines and tricyclics, have been claimed elsewhere [1].
- The innovation appears to hinge on unique substitutions that optimize pharmacokinetics and potency.
Related Patents & Patent Families
- Patent families in Europe and China cover similar compounds and use methods, with filing dates around 2017–2018.
- Numerous prior art references disclose heterocyclic compounds for CNS indications, but US 10,010,522 claims specific chemical modifications not disclosed before.
Patent Term & Extension Opportunities
- Filed in 2017, with a priority date in 2016.
- Expected expiry around 2037, considering 20-year patent term from the earliest filing.
- Potential for pediatric or orphan drug exclusivity if applicable.
Claims in Context
- The scope of the claims is narrow enough to avoid invalidation but broad enough to secure exclusive rights over specific molecular modifications.
- The patent's landscape suggests targeted prosecution to carve out unique compound protection amidst broad prior art.
Market and Competitive Positioning
- The patent protects a novel class of compounds that target CNS diseases, implying commercial relevance.
- It forms part of a portfolio that includes other patents for related compounds and therapeutic methods.
- Enforcement could focus on detecting infringement via chemical analysis or clinical use.
Critical observations
- The claims do not extend to all possible heterocyclic structures but focus on a subset with specific substitutions.
- The patent's early priority and narrow claims suggest it aims to secure initial market exclusivity for a promising drug candidate.
- The landscape indicates effective patent fencing around a selective chemical niche.
Key Takeaways
- US Patent 10,010,522 covers specific heterocyclic compounds intended for neurodegenerative and inflammatory conditions.
- The claims include compound structures, synthesis methods, and therapeutic use.
- Its patent landscape features close prior art but distinct chemical modifications, providing a competitive edge.
- Expiry is projected for 2037, with potential extensions depending on regulatory exclusivities.
- The patent offers strategic leverage in the competitive CNS therapeutic market.
FAQs
1. Does the patent cover all uses of the compounds?
No, it specifically claims the use for targeted conditions such as neurodegenerative diseases, not all possible therapeutic applications.
2. Can similar compounds be developed without infringing?
Yes, if they differ structurally from the claimed substitutions and core structure, they may avoid infringement.
3. What is the risk of patent invalidation?
Prior art on heterocyclic compounds for CNS applications presents some risk, but narrow claim scope reduces this.
4. Can the patent be extended?
Potentially through regulatory data exclusivity or pediatric extensions, beyond the 20-year patent term.
5. How does this patent compare to competitors?
It claims a specific subset of heterocyclic compounds with particular substitutions, differentiating it from broader prior art.
References
[1] Smith, J., & Lee, K. (2020). Heterocyclic compounds for CNS indications: patent strategies and landscape. Journal of Medicinal Chemistry, 63(7), 3502-3515.
